Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Stockholders Equity of $31.26 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $31.26B | +6.5% |
| 2024 | $29.35B | +13.0% |
| 2023 | $25.97B | +14.6% |
| 2022 | $22.66B | +20.8% |
| 2021 | $18.77B | +70.2% |
| 2020 | $11.03B | -0.6% |
| 2019 | $11.09B | +26.6% |
| 2018 | $8.76B | +42.5% |
| 2017 | $6.14B | +38.1% |
| 2016 | $4.45B | +21.7% |
| 2015 | $3.65B | +43.3% |
| 2014 | $2.55B | +29.8% |
| 2013 | $1.96B | +56.3% |
| 2012 | $1.26B | +158.7% |
| 2011 | $485.73M | -8.0% |
| 2010 | $527.82M | +33.0% |
| 2009 | $396.76M | -5.9% |
| 2008 | $421.51M | -8.2% |
| 2007 | $459.35M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.96B | +5.6% | +3.4% |
| June 30, 2025 | $29.94B | +6.1% | +1.9% |
| March 31, 2025 | $29.39B | +8.9% | +0.1% |
| December 31, 2024 | $29.35B | +13.0% | +0.1% |
| September 30, 2024 | $29.33B | +17.8% | +4.0% |
| June 30, 2024 | $28.21B | +17.4% | +4.5% |
| March 31, 2024 | $26.99B | +14.9% | +3.9% |
| December 31, 2023 | $25.97B | +14.6% | +4.3% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +6.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2007–2025 period, REGENERON PHARMACEUTICALS, INC.’s stockholders equity has grown by 6704.6% (from $459.35 million to $31.26 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: